A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A 2-period, crossover study to assess the effects of MK0683 (vorinostat) on the QTc interval in patients with relapsed or refractory advanced cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Vorinostat

Criteria

Inclusion Criteria:

• Patient has a histologically-confirmed metastatic or locally advanced solid tumor that has failed to respond to standard therapy, progressed despite standard therapy or for which standard therapy does not exist

• Patient has life expectancy of greater than 3 months

• Patient is able to swallow capsules

Exclusion Criteria:

• Patient has had chemotherapy, radiotherapy or biological therapy 2 weeks prior to taking study drug

• Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent

• Patient has active CNS metastases and/or carcinomatous meningitis

• Patient has primary central nervous system tumor

• Patient has a history of drug or alcohol abuse

• Patient has Hepatitis B or C

• Patient is HIV positive

• Patient has active infection or has received intravenous antibiotics, antiviral or antifungal agents 2 weeks before taking study drug